He aha nā Antibiotics i hoʻolālā ʻia e AI - a me kahi Enzyme hou i loaʻa - ʻo ia no nā kaʻina hana noiʻi Peptide

Pane wikiwiki

Hāʻawi ke kumu hoʻohālike iā ʻoe i kahi papa inoa moho no ke kumu kūʻai o ka holo helu. Hoʻomaka ka ʻāpana pipiʻi ma hope o kēlā: ka hoʻoholo ʻana i nā kaʻina e kūpono i ka synthesis, ka mea…

ʻO ka mea i hōʻike maoli ʻia e ka MIT antibiotic campaign a me ka hulina enzyme

he ʻaoʻao ʻaoʻao ʻelua kolamu o nā hoʻolaha ʻelua e hōʻike ana i nā mea hoʻokomo, helu helu, nā moho i hoʻopuka ʻia, moho ma ke kino

Hale Hana Mea Hoʻolako Peptides ʻenehana Peptide Ua hōʻike ʻia nā hoʻolaha ʻelua i ka ʻimi a me ka hoʻonohonoho mua ʻana i ka nui, ʻaʻole i hōʻoia ʻia nā moho lāʻau lapaʻau. ʻO ka Kelepona hana i hoʻohui ʻia i nā ʻano hoʻohālike i hoʻokumu ʻia i nā ʻāpana a me nā de novo generative 36 miliona pūhui wānana ma o nā kānana i 24 nā molekole i hoʻohui ʻia, ʻehiku o lākou he antibacterial (Krishnan et al., Kelepona, 2025). Hōʻike ka puʻu o ka gonorrhea track i ke kumukūʻai: 6,937,677 nā molekole i hana ʻia, 678 waiho ma hope o ke kānana ʻana, 80 hana mua ʻia no ka synthesis, 27 hoao, a wale no 2 o 27 hiki ke hoʻohui ʻia nā mea hoʻohui i hoʻāʻo ʻia.

He aha nā Antibiotics i hoʻolālā ʻia e AI - a me kahi Enzyme hou i loaʻa - ʻo ia no nā kaʻina hana noiʻi Peptide

Ua holo ke ala MRSA 29,014,974 i hoʻokumu ʻia nā molekala i 90 i koho ʻia, 22 kūʻai ʻia, a 6 ʻeleu ma 64 μg/mL, i hōʻike ʻia e nā mea kākau e like me ka track MRSA 27.3% ka helu ʻike maoli. He mea nui ka hui kepau: Hoʻopaʻa ʻo NG1 iā LptA, he mea hoʻolalelale kūkulu ʻia i waho i ʻike ʻole ʻia e nā lāʻau antibiotic, a me kona 0.5 μg/mL MIC kū'ē N. gonorrhoeae hele mai me kahi ho'ēmi CFU 3-log i loko o ke kumu hoʻohālike iole. Noho nā pathogens ʻelua ma luna o ka 2024 ʻO ka papa inoa o ka WHO ma ke ʻano he mea nui.

He ʻano hōʻike ʻokoʻa ka moʻolelo enzyme. Ua loaʻa hou nā ʻelele o ka hōʻike 198,290 nā pūʻulu hoʻohuli-transcriptase, kiʻi ʻia 3,564 nā ʻohana protein hoa moho, a hookiekieia 17 i nā hōʻike hiki ke heluhelu ʻia e ke kanaka. ʻO ka hōʻike pono'ī e lawe i ka "ART (kuhiakau)” lepili a ʻōlelo ʻia e kali ana nā ʻike i ka hōʻike hoʻokolohua. Hoʻomaopopo ka hōʻike kūʻokoʻa ʻaʻole i loiloi ʻia ka hōʻike a ua ʻike ʻia ka transcriptase like ʻole i kahi 2021 pepa jumbo-phage (Uea, 2026).

He aha nā Antibiotics i hoʻolālā ʻia e AI - a me kahi Enzyme hou i loaʻa - ʻo ia no nā kaʻina hana noiʻi Peptide

No ke aha e hāʻule ai nā ʻumi miliona o nā moho i kahi mau kakini i hoʻohui ʻia

Hōʻike nā hoʻolaha i ʻōlelo ʻia i ka synthesis a me nā hoʻokolohua hoʻokolohua hiki ke kāohi i nā hana ʻike kikoʻī. ʻAʻole lākou i hoʻokumu ua lawa ka wānana a i ʻole ka synthesis ka bottleneck nui i kēlā me kēia papahana peptide.. E loiloi i nā mea ʻelua.

Kūlike nā polokalamu peptide i ka pā like mai kekahi ʻaoʻao. Ua hōʻike ʻia kahi hoʻolaha peptide generative 86 o 100 Ua hana nā peptides i hoʻolālā ʻia, akā ua hoʻopaʻa ʻia kona hanauna i nā kaʻina ma lalo 50 koena, a 1 o 20 ʻAʻole hiki ke hoʻohui ʻia nā peptides benchmark (ApexGO, Nature Machine Intelligence, 2026). A 100% ʻO ka helu kūleʻa synthesis ma kahi 20-peptide benchmark ʻaʻole like ia me ka 86% hana ma 100 peptides, a ʻaʻole hoʻololi nā helu i kahi hydrophobic 40-mer.

He aha nā Antibiotics i hoʻolālā ʻia e AI - a me kahi Enzyme hou i loaʻa - ʻo ia no nā kaʻina hana noiʻi Peptide

Pehea e lilo ai ka hiki ʻana o ka synthesis i mea hoʻokomo i ka pae moho

ʻO nā pahu hoʻomaʻemaʻe ma mua a ma hope o ka hoʻololi ʻana i ka pseudoproline: ʻāpana hGH 23% → 69%, ʻāpana GB1 17% → 75%

Aia ka pono i loko o ka hana helu, ʻaʻole i ka laina ma hope o ia. ʻO ke kumu hoʻohālike i hoʻonohonoho ʻia e ka hana wānana wale nō e hoʻomau i ka hāʻawi ʻana i nā kaʻina lab i hiki ʻole i ka lab ke hana, a ʻo kēlā me kēia hui ʻana i hāʻule ʻole e uku i kahi pōʻai ʻaʻole hiki ke hoʻihoʻi ka hoʻolaha. Hiki ke ana ke kumukuai. A 2026 Nature Chemistry ao ana i 539 Ua ʻike ʻia nā kaʻina hana ua hoʻihoʻi ka pseudoproline i ka maʻemaʻe maʻemaʻe mai 23% i 69% no kahi ʻāpana hGH a mai 17% i 75% no kahi ʻāpana GB1, me nā kaʻina hoʻohui i hōʻailona ʻia e ka hoʻonui ʻana o ka piko deprotection ma luna 20% pili i ka hui mua (ʻO Tamás et al., Nature Chemistry, 2026).

Hōʻike ka hana like i ka mea e helu ai. Hoʻohui-hoʻoikaika i ke koena haku mele, ʻaʻole ke kaʻina pololei, lawe i ka hapa nui o ka hōʻailona wānana: E lilo(t-Keia), Me, ʻO Val a me Thr(t-Keia) hoʻonui i ka likelihood loa, ʻO Gln(Ua haʻi ʻo Trt) a ua hāʻawi nui ʻo Leu, pono nā kumu Gly-Ser a me Leu-Leu, a hoʻokomo pinepine ʻia ka hui ʻana 5 i 15 koena mai ka heleuma resin.

No ke kōkua: ʻElima mea hoʻokomo kūpono e hoʻohui i ka hana kūlana: hoʻohui ʻia-prone haku mele, nā hae kumu, ka lōʻihi e kū'ē i ka laulā i hōʻoia ʻia o ka synthesizer, paʻakikī hoʻololi, a me ka hoʻomaʻemaʻe pilikia. ʻO ke kaʻina helu maikaʻi ma ka hana a maikaʻi ʻole ma nā ʻelima a pau he mea pila, aole moho.

Ua wehe ʻia kahi nīnau hoʻohui. ʻAʻole ʻike ʻia ka ApexGO optimizer i wehewehe ʻia ma ka hana MIT e hoʻohālike i ka propensity aggregation, no laila, pono ka hoʻolālā-i-synthesis workflow i kēlā papa i hoʻohui ʻia ma waena o ka hoʻohālikelike hoʻohālike a me ka queue synthesis.

He aha ke ʻano o ka "validated" no kahi peptide i koho ʻia e AI

E hōʻoia i kēlā me kēia ala no kāna ʻano i manaʻo ʻia. ʻO ka hoʻomaʻemaʻe HPLC a me kahi hopena ʻike MS e pane i nā nīnau hoʻohui, akā ʻo ka hoʻopili wale ʻana iā lākou ʻaʻole ia e hōʻoia i ka hōʻoia orthogonal o kēlā me kēia hiʻohiʻona a i ʻole hōʻoia i ka mana nui a me ka ʻike..

ʻAno

Nīnau ia pane

ʻano kumu mua

hoa pili kino

Kūlana

Haalele CoA maʻamau

ʻIkepili

ʻO kēia ke kaʻina Mea Hoʻolako Peptide Synthetic kauoha ʻia?

LC-MS

Ka nānā 'ana i ka waikawa amino a i 'ole ka ho'onohonoho 'ana o MS/MS

I Q6B

Ua hōʻike ʻia ka lehulehu me ka wehewehe ʻole

Maemae

ʻEhia ka nui o ka peptide i loaʻa?

RP- Purepeptides HPLC

HPLC ma kahi kemika ʻokoʻa

I Q2(R2)

Pākēneka ʻāpana wale nō, ʻaʻohe kikoʻī ʻano

Ka mana

Hana ʻia ma ka hoʻāʻo?

ʻIke hana

Bioassay Orthogonal

I Q6B Punawai Peptide

ʻAʻole i hōʻike ʻia no ka nui o ka noiʻi

Maʻiʻo

Pehea ka nui o ka peptide i loko o ka vial?

Ka helu helu

Kaulike lehulehu

I Q6B

ʻAʻole ʻike ʻia ka peptide maʻamau

Endotoxin

Palekana ka mea no ka ʻōnaehana hoʻāʻo?

LAL hoao

Nā mana kūpono-kūpono

USP <85>

ʻAʻole i ʻōlelo ʻia ka palena

No ka hoʻāʻo ʻana ma ke kelepona, e ho'āpono i ka mana endotoxin mai ka naʻau hoʻāʻo, ka noonoo a me ke keakea. ʻAʻole nā ​​palena K/M paʻamau paʻamau. Endotoxin, ʻokoʻa nā ʻano microorganism ola a me nā ʻāpana a pono nā mana kūpono inā pili.

He aha ka mea e mākaukau ai ka peptide material assay, a pehea e wehe ai i nā mea waiwai

ʻO nā mea peptide mākaukau ʻo Assay ka mea nona ka hana i ka assay i hoʻokaʻawale ʻia mai ke keakea ponoʻī o ka assay.. Loaʻa ka counterscreen hōʻuluʻulu maʻamau no ka mea ʻo nā peptides i hōʻuluʻulu ʻia ma nā haʻahaʻa haʻahaʻa a i waena o nā micromolar., hana ʻāpana 100 i 500 nm ma kēlā ʻaoʻao o kēlā pūmua hoʻopaʻa i ka pae picomolar a ʻike ʻole ʻia e ka maka (Auld, Pelekania & ʻO Dahlin, Manual alakaʻi hōʻike, 2017).

Maʻemaʻe ma mua a ma hope o ka hoʻoponopono pseudoproline Maʻemaʻe ma mua a ma hope o ka hoʻoponopono pseudoproline, e like me ka manao mai ke kumu i oleloia. Maʻemaʻe ma mua a ma hope o ka hoʻoponopono pseudoproline. ʻikepili pā hui: ʻāpana hGH: Synthesis maʻamau 23, Pseudoproline 69; ʻāpana GB1: Synthesis maʻamau 17, Pseudoproline 75. Puna: ʻO Tamás et al., Nature Chemistry 18:677–685 2026-03-20. Maʻemaʻe ma mua a ma hope o ka hoʻoponopono pseudoproline 0 25 50 75 100 Synthesis maʻamau Pseudoproline 23 69 ʻāpana hGH 17 75 ʻāpana GB1 Puna: ʻO Tamás et al., Nature Chemistry 18:677–685 (2026-03-20)

E koho i ka hui, pōʻino membrane, adsorption a me nā kaʻa kaʻa no ka hoʻāʻo maoli. ʻAʻole nā ​​palena o ka ʻae ʻia ʻana o ke ao holoʻokoʻa, a hiki i ka mea holoi ke hoʻololi i ka hana peptide hana membrane.

He aha ke aupuni e hoʻokaʻawale i ka ʻōlelo hoʻohiki helu mai ka hana i hōʻoia ʻia

Hoʻokaʻawale ke aupuni i nā mea ʻelua ma ka mālama ʻana i ka hoʻopuka o ke kumu hoʻohālike a me ka hopena i ana ʻia ma kahi kaʻawale, nā moʻolelo i hoʻololi ʻia, a ma ka hōʻole ʻana i ka hoʻokuʻu ʻana i kekahi no kekahi. Ka Mahele 11 ʻO ka ʻōlelo audit-trail ka wehewehe ʻana i kahi moʻolelo uila e like me ka hui pū ʻana o nā kikokikona, kiʻi kiʻi, ʻikepili, leo, kiʻi kiʻi a i ʻole nā ​​hōʻike ʻike ʻē aʻe i hana ʻia, hoʻololi ʻia, mālama ʻia, waihona, kiʻi ʻia a puʻunaue ʻia e kahi ʻōnaehana kamepiula, a hana i nā ʻōnaehana kamepiula a me kā lākou mau palapala i lalo o ka nānā ʻana o FDA (21 Mahele CFR 11, eCFR).

Hoʻoponopono kēlā i nā moʻolelo, ʻaʻole kūpono ke kumu hoʻohālike. ʻAʻohe mea i loko o ke kānāwai i ʻōlelo ʻia he kūpono ke kumu hoʻohālike no ka mea ua hoʻopaʻa ʻia kāna mau huahana. Hōʻike ka hoʻolaha enzyme i ke kumu o ka ʻokoʻa: ʻO ka ʻōlelo ponoʻī a ka hōʻike ʻaʻole ʻike ʻia ka hana e noho ana ma ka ʻaoʻao o nā reruns he ʻumi ʻaʻole i hōʻea hou i ka array e like me ka ʻike..

Koi

Kūlana

He aha ka mea e neʻe ai i mua

36 miliona pūhui i hana ʻia

Hōʻike ʻia, loiloi ʻia e nā hoa

ʻAʻohe mea ʻē aʻe

6 o 22 ʻO nā pūhui MRSA e hana ana i loko o ka vitro Mea Hana Ho'āʻo Peptide

Hōʻike ʻia, loiloi ʻia e nā hoa

Hoʻopili kūʻokoʻa

ʻO ka maikaʻi o NG1 i loko o kahi hoʻohālike iole

Hōʻike ʻia i nā holoholona wale nō

ʻAʻole ʻae ʻia ke koi lapaʻau

Hana ʻōnaehana ART

Kuhiakau, ʻaʻole i nānā ʻia e nā hoa

Hōʻike hoʻokolohua

ʻO ke kūlana hoʻohālike e wānana i ka holomua o ka synthesis

ʻAʻole i hoʻokumu ʻia

ʻIkepili hoʻohui manaʻo

He aha ka polokalamu peptide e hoʻololi i kēia manawa

ʻO kahi papa kuhikuhi me kahi nui peptide, ʻO kāna CoA a me nā paʻi analytical i waiho ʻia ma ka ʻaoʻao o kahi pale queue synthesis

E hoʻololi mua i ka hana kūlana, a laila ka pūʻolo analytical, a laila nā moʻolelo. Maikaʻi: hoʻohui i ka helu kūpono ma mua o ka papa inoa pōkole, e koi i kahi ala ʻike orthogonal ma kēlā me kēia ʻāpana, holo i nā pale pale aggregation ma mua o ka manaʻoʻiʻo i nā mea hana mua, a mālama i nā hua hoʻohālike a me nā hopena i ana ʻia ma nā moʻolelo i hoʻokaʻawale ʻia me kahi ala hoʻoponopono.

ʻO kahi synthesis ka palena, ʻoi aku ka nui o ke kamaʻilio mea kūʻai aku ma mua o ke kumu hoʻohālike. ʻO kā mākou hui ma MOL Changes e holo i ka Fmoc solid-phase synthesis me ka HPLC reverse-phase a me ka ʻikepili spectrometry nui i hāʻawi ʻia me kēlā me kēia kauoha peptide maʻamau., uhi N-terminal, C-terminal a me ka ʻaoʻao-chain hoʻololi me ka cyclization, nā alahaka disulfide, nā ʻakika amino kūlohelohe ʻole a me ka hoʻohui ʻana i ka isotope paʻa, a me nā unahi mai nā milligrams i nā kilokani ma o ka lyophilization. Hoʻohana nā hale hana i ka hoʻokaʻawale ʻelua, ʻO ka kānana HEPA a me ka wahi paʻi maikaʻi, me ka hoao ana i ka maemae, maʻiʻo, endotoxin, pH a me ka sterility ma lalo o kahi hoʻoponopono nānā ponoʻī.

pukaaniani

Hana

30 lā

Hoʻohui i nā mea hoʻokomo kūpono ʻelima i ka hana hoʻonohonoho; hoʻoponopono i nā CoA hope ʻekolu no ka nalowale ʻana o ka ʻike a i ʻole ka ʻikepili maʻiʻo

60 lā

E hoʻohui i kēlā me kēia ʻano hoʻomaʻemaʻe me kahi ʻano ʻike orthogonal; hoʻohui i ka pale pale i ka protocol assay maʻamau

90 lā

E hoʻokaʻawale i nā moʻolelo kumu hoʻohālike mai nā moʻolelo i ana ʻia me ka hoʻololi ʻana a me ke ala loiloi; e kākau i ka palapala hoʻopaʻa inoa kuleana no kēlā me kēia papahana hana

Nīnau pinepine

Ke hana nei ka 86% peptide hit rate hōʻike AI peptide design paʻi i nā hoʻolaha liʻiliʻi?

ʻAʻole. ʻO ka 86 o 100 Ua hana nā peptides i hoʻolālā ʻia e kūʻē i hoʻokahi 11 nā pathogens, oiai ka Kelepona nā pepa 27.3% he hana ma waena 22 synthesized small molecules. Nā helu like ʻole, wahi kemika ʻokoʻa, nā wahi hoʻomaka ʻokoʻa.

No ke aha i nui ʻole ai nā moho i hana ʻia e AI i ka synthesis?

No ka mea, ʻaʻole i kāohi ʻia ka hanauna e nā ala synthesis. ʻO ka Kelepona hōʻike wale nā ​​mea kākau 2 o 27 i hoʻāʻo ʻia nā pūhui i hoʻokahi ala i hiki ke synthesizable, a ua ʻoki ʻia kēlā ʻāpana no ka mea ʻaʻole i hiki ke loaʻa kekahi o kāna mau pūhui ʻelima i loko o nā manawa maʻamau a me nā koina..

Ua nānā ʻia ka ʻike ʻana o ka enzyme?

ʻAʻole. ʻAʻole i nānā ʻia ka hōʻike ʻenehana, lepili i ka ʻōnaehana he kuhiakau, a ke ʻōlelo nei ke kali nei nā ʻike i ka hōʻike hoʻokolohua.

E pili ana nā kūlana ICH a me USP i nā peptides pae noiʻi?

I Q2(R2) a me Q6B hoʻomalu i ka hōʻoia analytical a me ka hoʻonohonoho kikoʻī no nā huahana lāʻau. No ka mea noiʻi-mākaukau, e hoʻohana iā lākou e like me ke ʻano o ke ʻano o ke ʻano: ʻikena orthogonal, hōʻike kikoʻī, a ʻo nā palena endotoxin i ʻōlelo ʻia e haʻi mau iā ʻoe inā he mea ko ka CoA.

Pehea e hoʻololi ai ka peptide synthesis feasibility prioritization i kahi hana kūlana?

ʻO ka hoʻohui ʻana i ka hoʻopaʻa ʻana, nā hae kumu, lōʻihi e kū'ē i ka laulā synthesis i hōʻoia ʻia, paʻakikī hoʻololi a me ka hoʻomaʻemaʻe ʻana me ka hana i wānana ʻia, a mālama i kahi hana kiʻekiʻe, ke kaʻina pilikia ma ke ʻano he mea pila ma mua o ka moho.

Ka hopena

Hōʻike ka hoʻolaha antibiotic MIT a me ka huli ʻana i ka enzyme e hiki i kahi loop design-to-data ke ʻimi i nā wahi nui a hoʻihoʻi i nā kuhiakau mua.; ʻAʻole lākou e hōʻike i kahi mea hoʻohui a i ʻole peptide he lāʻau lapaʻau. ʻO ka Kelepona kū ka hana ma nā ʻano maʻi ʻiole, kū ka hoʻolaha peptide i nā MIC in vitro, a ke noho nei ka ʻōnaehana enzyme he kuhiakau e kali ana i nā hoʻokolohua. No nā lāʻau antibiotic i hoʻolālā ʻia e AI a me nā kaila hana noiʻi peptide, ʻO nā loulou nāwaliwali ka hiki ke hana, hōʻoia orthogonal a me ka hoʻokele moʻolelo, a ʻo kēlā me kēia mea he pilikia ʻenekinia hiki i kahi papahana ke hoʻoponopono i kēia hapaha.

ʻO ka hoʻololi a mākou e manaʻo nei e ʻike ma waena o ke kahua he ʻekolu: ʻO ka hoʻolālā ʻike hiki ke hoʻonohonoho i nā moho ma o ka hiki ke hana ʻia, ʻO nā ʻikepili orthogonal-by-default e manaʻo nei e hiki ke alakaʻi hewa kekahi ala hoʻokahi, a koi i nā lepili e hele pū ana me ka ʻikepili no laila ʻaʻole i heluhelu ʻia kahi hopena kiʻi ʻiole ma ke ʻano he lāʻau lapaʻau. ʻO nā polokalamu e hoʻohana i nā mea ʻekolu e hoʻohuli i nā papa inoa moho AI i mea peptide mākaukau mākaukau ma mua o nā papahana e mālama i ka hōʻoia ʻana ma ke ʻano he hana i lalo..

ʻO kahi hana mua pono e lawe i kahi kaʻina paʻakikī a me kāna ʻike i manaʻo ʻia i kahi kamaʻilio ʻenehana. E nīnau i ka mea e pono ai ke komo i loko o ka pūʻolo analytical ma mua o kou kau inoa ʻana i ka CoA, a noi i kahi laʻana CoA a me ka pūʻolo analytical no laila he palapala ka pane ma mua o ka ʻōlelo hoʻohiki. ʻAʻohe mea ma ʻaneʻi he ʻōlelo aʻo lapaʻau a hoʻoponopono; ʻO nā hoʻoholo e pili ana i ka holomua o ka moho no kāu mau loiloi ʻepekema a me ka lāʻau lapaʻau ponoʻī.

Hōʻike ka mea hoʻopuka: Hāʻawi ʻo MOL Changes i nā lawelawe peptide a he hoihoi koʻikoʻi i kēia kumuhana. ʻO nā lālā lawelawe a me nā ʻōlelo hiki ke koi i nā mea hoʻolako; ʻO ka loaʻa a me ka hana ʻana no kahi kūkulu kikoʻī e koi i nā hōʻike kikoʻī o ka papahana.

Xiaoxia Chen

Xiaoxia Chen

Laau Laau Hou R&D ʻenehana Kaʻike kumu: Loaʻa ka pahuhopu, pilina hana-hana (SAR) kālailai, peptide-lāʻau conjugates (Nā PDC), a me ka hoʻomohala ʻana i nā peptides anti-kahiko a me ka metabolic.

Pilikino: Ua alakaʻi ʻo Xiaoxia Chen i ka ʻike mua ʻana a me ka noiʻi preclinical no kekahi mau lāʻau peptide metabolic a me ka tumor-targeted.. ʻAʻole wale ʻo ia i mākaukau i ka nānā ʻana i nā hale waihona puke peptide, akā akamai nō hoʻi i ka hoʻohana ʻana i ka biology computational kōkua AI no ka hoʻolālā ʻana o ka de novo peptide sequence.. I kēia manawa, ke alakaʻi nei ʻo ia i kahi hui i hoʻolaʻa ʻia i ka noiʻi hohonu a me ka hoʻomohala ʻana o nā agonists multifunctional hanauna hou (like me pālua- a i ʻole nā ​​peptides hoʻohaʻahaʻa momona ʻekolu) a me nā peptides hoʻoponopono hou i ke kino.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana